![]() Method of producing derivatives of oxazolidinon as l-isomers or mixture of d- and l-isomers, or thei
专利摘要:
Novel aminomethyl oxooxazolidinyl benzene derivatives, including the sulfides, sulfoxides, sulfones and sulfonamides, such as (I)-N-[3-[4- (methylsulfonyl) phenyl] -2- oxooxazolidin -5- ylmethyl] carbamic acid, methyl ester possess useful antibacterial activity. 公开号:SU1505442A3 申请号:SU843752502 申请日:1984-06-06 公开日:1989-08-30 发明作者:Адельман Грегори Вальтер 申请人:Е.И.Дюпон Де Немур Энд Компани (Фирма); IPC主号:
专利说明:
31505 in the form of a 1-isomer or a mixture of d-Il-isomers, where Y and A have the indicated meanings; L - iodine or hydroxy group in the form salts with p-toluenesulfonic acid are reacted with an alkali metal azide when heated in an inert organic solvent medium and the target product, where B is an azido group, is isolated or, if necessary, converted to the target;: product, where B is an amino group, by reduction and the target product, where B is an amino group, if necessary, is reacted with kansulfonyl chloride or with anhydride, acid chloride or carboxylic acid ester of the formula Rjcooh where RJ has the meanings indicated for Rj, in addition to aminomethyl or azidomethyl, and the target product, where Rg is chloromethyl, if necessary, is reacted with an alkali metal azide when heated in an inert organic solvent and the desired product, where R is azidomethyl , if necessary, translate into 0 five 0 the left product, where R, is aminomethyl, by reduction and, if necessary, in the presence of a free amino group, the target product is added as an acid salt with an acid. Priority featured: 06.06.83 when Y is hydrogen; A is in position 4 of the benzene ring and means C, -C,}. Is an alkylthio group, C (-C4 alkylsulfinyl or C, alkylsulfonyl, B has the indicated values. 14.02.84 when Y is hydrogen; A is in position 3 of the benzene ring and is C -C-acyl, C, alkyl, methoxy, methylthio, trifluoromethyl, or nitro, or A is in position 4 of the benzene ring. and means C-C-alkyl, optionally substituted with 1 to 3 halogen atoms, C-C-alkenyl, cyano, C, -C-alkock-SI-, a group of the formula COR, in which hydrogen, C, is C4-alkyl or cyclohexyl, or a group of the formula "to, -C-SNZ where rt. 2 hydroxy or methoxy groups, or Y and A vseret form a 3,4-methylenedioxy group, B has the indicated values. The invention relates to a process for the preparation of new oxazolidinone derivatives as 1-isomers or a mixture of d-and 1-isomers, or their additive salts with acids, which have antibacterial action and can be used in medicine. The purpose of the invention is the creation of a method for obtaining new oxazazolidinone derivatives with antibacterial action 1 with increased productivity of action in vivo and weakened side effects. The examples below illustrate the invention. In the following examples, the values of A and B are given for compounds of the formula: J. 40 five -50 55 Example 1. Preparation of (dl) -5-azidomethyl-3-4- (methylsulfonyl) phenyl -2-oxazolidinone (I, BH,). Part A. Preparation of (dl) -5-yodomethyl-3-4- (methylsulfonyl) phenyl 2-oxazolycinin. A mixture of 50 g (345 mmol) of (dl) -5-chloromethyl-3-4- (methylsulfonyl) phenyl 2-oxazolidinone and 100 g of sodium iodide in 300 ml of 2-butanol is heated under reflux overnight .. Then cooled and poured into 1 l of an ice-water mixture, sodium sulfate was added until the yellow color completely disappeared, the mixture was filtered and washed with water to obtain 61.7 g. 1 m-methyl compound t so pl. 175.5-177 C. This material is further recrystallized from 370 ml of acetonitrile, resulting in get 44,8 g of product with so pl. 177.5-179 ° C. Part B. A mixture of 7.6 g (20 mmol) of (dl) -5-fiOA methyl 3-4- (methylsulfonyl) phenylT-2-oxazolidinone and 4 g of sodium azide in 150 ml of dry DMAC is kept at 125 ° C for 3 hours. Then it is drunk in a mixture of ice water. The product is extracted with three portions of chloroform, the extracts are dried over sodium sulfate and concentrated to give a semi-solid paste, which is stirred with diethyl ether, filtered and dried to obtain 4.7 g of material. The latter was recrystallized from 14 ml of acetonitrile, resulting in 2.2 g of an azidomethyl compound with a mp. 152, 3-153, 5 Example 2. Preparation of (1) -5-azidomethyl-3- 4- (methylsulfonyl) -phenyl -2-oxazolidinone (I; A 4 methyl-SO; B N,). Part A. Preparation of (1) -3-hydroxymethyl-3-4 (methylsulfonyl) phenyl -2-oxazolidine on 4-methylbenzenesulfonate 1 (I; A 4-methyl-50,; In OSO, CeH-methyp). A solution of 5.00 g of (dl) -5-oxymethyl-3-L4- (methylsulfonyl) phenyl | -2-oxazolycinone in 30 ml of pyridine dryung is stirred at and a solution of 3.7 g of p-toluenesulfonyl chloride in 10 ml of P1-fidine is gradually added to it. After the addition, the mixture is stirred for another 1 hour, and then crystallized to a semi-solid mass, to which a few drops of water are added, resulting in the generation of heat. The mixture is drawn into an ice-water mixture, filtered and washed with water. The result is 4.02 g of product with so pl. 187.1-188.6 ° C. Part B. A mixture of 3.5 g of (1) -5-hydroxymethyl-3-4- (methylsulfonyl) phenyl -2-oxazolidinone, 4-methylbenzenesulfonate, with 2 g of sodium azide in 20 ml of DMF is filled to 90-100 ° C. After 1 hour, the mixture is cooled and diluted with an ice-water mixture, as a result of which the product crystallizes. Then it is filtered and the mixture is washed with water, and 1.25 g of substance is obtained with a mp. 146.5-148.5 ° C. The product is crystallized from methanol to obtain a substance with so pl. 148.9-149.4 C. Q 15 20 five 0 five 0 five 0 five In accordance with the procedures that are described. in npHMtipax 1-2 get azides in the course of fever 3-5, are given in table. one. Example 6. Preparation of (dl) -5-am11nomethyl-3-4- (methylsulfonone 1) phenyl -2-oxazolidine salt of trifluoro-acetic acid (A 4-CH); B - NHj.). A solution of 1.1 g of (dl) -3-azidomethyl-3-4- (methylsulfonyl) phenyl 1 -2-oxlsolidinone in 75 ml of trifluoroacetic acid and 0.5 g of 10% palladium on charcoal in hydrogen at an overpressure of approximately 50 (cubes / sq., 3.5 KG / KB, cm for 1 h. The mixture is further filtered and concentrated, resulting in a yield of 0.8 g of product with mp 158-170 ° C (with decomposed1). Example 7. Prepare C1) -5-aNniHOMeT.4n-3-4- (methylsulfonpl) f-Hiij J-2-oxazolidinoma (I; L 4-methyl-SO; B f. Hj), A mixture of 3.48 g (0.0177 mol) (1) -5-aza; w etIgl-3-4- (meth., 1-phyl) fs-HKnj-2-i xazo.ch ,, i: yun, 11 t-vi 1,3-propane 1-thiol and 15 ml of triethyl-hsna in 30 ml of methanol ni uepxaiBaiOT at 40-5P during 15Y, |; ylepich nitrogen with a noticeable speed. After you turn off the output: geylch nitrogen solution con; e: triruk T under po) 1tizhenn- (pressure, the residue is mixed with diethyl ether, h, the raw material is filtered and dried, due to chelate O get 3.09 g of the substance with 137-142 C. р are poured into approximately 200 ml of absolute alcohol at the temperature of refluxing (some amount of The brown solid product — ha (remains nrragrotroris (gms) and filtered. The product crystallizes to give 2.46 g of the substance with mp 146.6-147.1 ° C. Example 8. Preparation of (1) -5- aminomethyl-3- 4- (methylsulfonyl) phenyl-2-oxazolidinone (I; A 4-methig1-50; B NHj). 2.00 g (6.75 mmol) of (1) -5-azido-methyl-3- (methylsulfonyl) phenyl 1 -2-oxazolidinone in 25 ml of 1,2-dimethoxy ethane is stirred in a stream of nitrogen, adding to it 3, 2 ml of trimethyl phosphite in 5 ml of 1,2-dimethoxyethane. The mixture becomes warmer and a rapid release of nitrogen is observed. The mixture is then concentrated to give a brown resin. The resin is stirred with water, in which case the solid material crystallizes. It is dissolved in water by adding dilute acetic acid to a pH of 4, filtered and the water is alkalinized by adding a concentrated solution of ammonium hydroxide. Obtain 0.94 g of product with so pl. 129-132.8 C. Example 9. Preparation of (1) -5- aminomethyl-3- 4- (methylthio) phenyl -2-oxazolidinone (I; A 4-methyl-5; B amino). A mixture of 30.3 g (115 mmol) of (1) -5-azidomethyl-3-4- (methylthio) phenyl -2-oxazolidinone, 13.1 ml of 1,3-propanedithiol and 18.2 ml of triethylamine in 150 ml methanol is stirred at ten 15 N mixed together with diethyl ether and filtered to obtain 2.72 g of material with so pl. 174.0 - 181 ,. The material is stirred with water, acidified with acetic acid, filtered and washed with water to obtain 2.60 g of material with m.p. 194.5 - 196.1 ° C. It is dissolved in a boiling mixture of 70% ethanol with water, acidified with acetic acid, cooled and filtered, yielding 1.65 g of product with m.p. 203.3-204.3 ° C. Calculated,%: C 40.95; H 3.70; 7.35. C ,, H, C1. ,, S Found,%: C 40.82; H 3.70; 7.10; 7.15. Example 14. Preparation of (1) -N50 ° C for 8 hours. Then its concentration is 20 (methylsulfonyl) phenyl -2-oxotriate, the residue is stirred with an aqueous solution of citric acid, filtered and the filtrate is alkalinized by adding a concentrated solution of ammonium hydroxide. The liquid is filtered to obtain 16.5 g of product with so pl. 160-162 C. In accordance with the procedures of Examples 6-9, the following lg-amines of Examples 10-11 are obtained, given in Table. 2 thirty oxazolidin-5-ylmethyl-acetamide (I; A 4-methyl-802 ;; —B NHCOCH). 2.00 g (7.4 mmol) of (1) -5-aminomethyl-3-4- (methylsulfonyl) phenyl -2-25 oxazolidinone in 10 ml of pyridine is cooled in an ice / water mixture, the dosage is 0.72 ml of acetic anhydride. The mixture is further stirred for 10-20 minutes, and then diluted with an ice-water mixture. The solid material is filtered and washed with water, get the product with so pl. 191.9 - 192.9 ° C. After recrystallization from acetonitrile, 1.01 g of product is obtained with mp. 192.7-193.2 C. EXAMPLE 12 Preparation of (1) -N- (3-4- (methylsulfonyl) phenyl 1 -2-oxo-oxazolidin-5-ylmethyl-formamide (I; A 4-methyl-30; B NHCHO) . A solution of 1.00 g (3.70 mmol) of (1) -5-aminomethyl-3- 4- (methylsulfonyl) phenyl 1-2-oxazolidinone in 10 ml of 2-propanol containing 2.5 ml of ethylforma- This is kept at reflux for 24 hours. The mixture is then cooled and diluted with diethyl ether to give 0.96 g of material which crystallizes from 9.5 ml of acetonitrile to give 0.65 g of product from m.p. 190-191.6 p. Example 13. Obtaining (1) - 2,2-dichlo-K- (methylsulfonyl) oxazolidin-5-ylmethyl-acetamide (I; A 4-methyl-802 ;; —B NHCOCH). 2.00 g (7.4 mmol) of (1) -5-aminomethyl-3-4- (methylsulfonyl) phenyl -2-25 oxazolidinone in 10 ml of pyridine is cooled in an ice / water mixture, the dosage is 0.72 ml of acetic anhydride. The mixture is further stirred for 10-20 minutes, and then diluted with an ice-water mixture. The solid material is filtered and washed with water, get the product with so pl. 191.9 - 192.9 ° C. After recrystallization from acetonitrile, 1.01 g of product is obtained with mp. 192.7-193.2 C. Calculated,%: C 49.99; H 5.16; N 8.97. Navdo,%: C 49,482; H 5.17; N 8.93; 8.88. Example 15. Preparation of Cl) N- I 3- (4-methylsulfonyl) phenyl 1 -2-oxo-oxazolidin-5-ylmethyl 7-methanesulfonamide (I; A 4-methyl-30; B methyl). A solution of 1.00 g (3.70 mmol) of (L) -5-aminomethyl-3-4- (methylsulfonyl) phenyl -2-oxazolidinone in 50 ml of dry pyridine is stirred on an ice bar 40 phenyl -2-oxooxazolidin-5-ylmethyl - 50 gradually added 2.3 ml of it -acetamide (I; A 4-methyl-50 ,,; In NHCOCnClj). A mixture of 2.00 g (7.4 mmol) of (1) -5-aminomethyl-3-4- (methylsulfonyl) phenyl1-2-oxazolidinone, 2 ml of methyldichloroacetate and 10 ml of ethanol is heated under reflux in a a stream of nitrogen for 5 hours. Then the mixture is concentrated under a lower pressure of methane sulfonyl chloride. After the addition is complete, 3 drops of water are added to this solution and the whole mass is concentrated. The residue is stirred with Water and a few drops of concentrated hydrochloric acid are added to the mixture to render the whole solution acidic. The precipitated material is filtered, washed N mixed together with diethyl ether and filtered to obtain 2.72 g of material with so pl. 174.0 - 181 ,. The material is stirred with water, acidified with acetic acid, filtered and washed with water to obtain 2.60 g of material with m.p. 194.5 - 196.1 ° C. It is dissolved in a boiling mixture of 70% ethanol with water, acidified with acetic acid, cooled and filtered, yielding 1.65 g of product with m.p. 203.3-204.3 ° C. Calculated,%: C 40.95; H 3.70; 7.35. C ,, H, C1. ,, S Found,%: C 40.82; H 3.70; 7.10; 7.15. Example 14. Obtaining (1) (methylsulfonyl) phenyl -2-oxo0 (methylsulfonyl) phenyl -2-oxo0 oxazolidin-5-ylmethyl-acetamide (I; A 4-methyl-802 ;; —B NHCOCH). 2.00 g (7.4 mmol) of (1) -5-aminomethyl-3-4- (methylsulfonyl) phenyl -2-5 oxazolidinone in 10 ml of pyridine is cooled in an ice / water mixture, the dosage is 0.72 ml of acetic anhydride. The mixture is further stirred for 10-20 minutes, and then diluted with an ice-water mixture. The solid material is filtered and washed with water, get the product with so pl. 191.9 - 192.9 ° C. After recrystallization from acetonitrile, 1.01 g of product is obtained with mp. 192.7-193.2 C. Calculated,%: C 49.99; H 5.16; N 8.97. Navdo,%: C 49,482; H 5.17; N 8.93; 8.88. Example 15. Preparation of Cl) N- I 3- (4-methylsulfonyl) phenyl 1 -2-oxo-oxazolidin-5-ylmethyl 7-methanesulfonamide (I; A 4-methyl-30; B methyl). A solution of 1.00 g (3.70 mmol) of (L) -5-aminomethyl-3-4- (methylsulfonyl) phenyl -2-oxazolidinone in 50 ml of dry pyridine is stirred on ice ba5 0 gradually added 2.3ml methanesulfonyl chloride. After the addition is complete, 3 drops of water are added to this solution and the whole mass is concentrated. The residue is stirred with water and a few drops of concentrated hydrochloric acid are added to the mixture to render the whole solution acidic. The precipitated material is filtered, washed water and dried, get 0.77 g of substance with so pl. 216.7-220.7 C. It is crystallized from a mixture of acetonitrile and water in a 4: 1 ratio and gives 0.51 g of the product with m.p. 219.7-220.7 ° C. Example 16. Preparation of (1) -N- (methylsulfonyl) phenyl -2-oxo-oxazolidin-5-ylmethyl1-carbamic acid, methyl ester (I; A i -metsl-SO; AT NHCOj-methyl). A mixture of 5.41 g (0.02 mol) of (1) -5-aminomethyl-3-4- (methylsulfonyl) Fe solution 5 g (16.1 mmop) (dl) -2-chloro-H-Gs-4- ( 1-methylethyl) phen. 1 -2- gsooksazolidnn-5-shmethyl i-pcetamad in 50 ml of dry dimethyl sulfoxide and 1.5 g of sodium azide are mixed, keeping it at 90 ° C in a stream of dry nitrogen for 5 hours. Next, the mixture is concentrated under reduced pressure and the residue is mixed with vpd. Partly crystallized tpsrdy: mat Nyl -2-oxazolidinone in 50 ml of tetra-5NYa- is separated and stirred on an ice bath while standing on an ice bath, adding a solution of 2 ml of methyl chloroformate in 10 ml of tetrahydrofuran together with 2 and. the solution is hydrated, resulting in 5.8 g of product. The last per. Christams are taken from ethyl acetate and 3.4 g of product are obtained with a melting point of 122.425. sodium oxide to maintain a maximum of 20 123.4 ° C (with decomposition). Thin layer h The pH in the range of 10-11. Then this mixture is stirred for 45 min after adding methyl chloroformate was completed. Organic solvents are removed. under reduced pressure and the residue diluted with water, argument pH to 7, solid material is filtered and washed it with water, get 6.5 g product with t.pp. 210-211 C. His re-ZO crystallized from acetonitrile and get 3.5 g of the product with so pl. 214-215 p. After additional recrystallization, the melting point of the sample reaches 216, 9-21 7, 6 C. Calculated,%: C 47.55; H 4.91; N 8.53. 35 silica chromatogram using chloroform: methanol: 9: 1 for elution: g: C1: indicates that the product is the starting compound with the desired product. The mixture is used in the subsequent stage without a preliminary CLEANING. Part B. A suspension of 3.4 g (dl) of 2-azido- | 314- (1-methylethyl) phenyl 1 -2-oxoc.sato1 - lidin-5-ylmet1: W of 1-acetyl imide in 50 ml ethanol, 5 ml of water and 5 ml of acetic acid, containing 0.5 g of 10% palladium on charcoal, are mixed, simultaneously iiponycxioioT through a solution of hydrogen through a feed pipe. The reaction is continued for 3 hours, after which the solution is filtered and concentrated. The residue is stirred with water and the residue is concentrated with a concentrated solution of ammonium hydroxide, resulting in the formation of a gummy material. It is extracted with ethyl acetate:, dried over sodium sulfate, and the solution is concentrated. The residue is stirred with diethyl ether and filtered. Obtain 1.4 g of the product with so pl. 82-92 ° C. The latter is recrystallized from 10 ml of ethyl acetate, adding to it a few drops of triethytamine, and 0.84 g of product is obtained with a volume of 105-107 ° C. C ,, H, gObNjS %,%: C, 47.55; 47.46; H4.88 4.81; N 8.73; 8.62. ot -47.7 ± 0.4 ° (in acetonitrile). Similarly to the foregoing, by carrying out the corresponding acylhalogenides, isocyanates, chloroformate ester, or other esters with amines of the general formula , -f I- L.:NHj .55 obtain the compounds of examples 17-95, are given in table. 3. Example97. Preparation 1-2 Example 96. Production (dl) -2-azido-N- | s - 4- (methylsulfonyl) phenyl -. amino-N-3-4- (1-methylethyl) -phenyl-2-oxooxazolidin-5-ylmethyl-acet1, 2-oxooxazolidin-5-ylmethyl-acet-amide (I; A 4-CHjSOi; IN NHCOCH N.) . 0 amide (I; A - (CH-) CE; B NHCOCK - amine). Part A. A solution of 5 g (16.1 mmop) (dl) -2-chloro-H-Hz-4- (1-methylethyl) phen. 1 -2- gsooksazolidnn-5-shmetil i-pcetamada in 50 ml of dry dimethyl sulfoxide and 1.5 g of sodium azide are mixed, keeping it at 90 ° C in a stream of dry nitrogen for 5 hours. The mixture is then concentrated under reduced pressure and the residue is stirred with vpdo11. The partially crystallized TPCRd: Mats5HpH- is separated and solidified upon standing, resulting in 5.8 g of product. The last per.crystallite from ethyl acetate and obtain 3.4 g of product with mp, 125.45 ABOUT five 0 five 0 silica chromatogram using chloroform: methanol: 9: 1 for elution: g: C1: indicates that the product is the starting compound with the desired product. The mixture is used in the subsequent stage without a preliminary CLEANING. Part B. A suspension of 3.4 g (dl) of 2-azido- | 314- (1-methylethyl) phenyl 1 -2-oxoc.sato1 - lidin-5-ylmet1: W of 1-acetyl imide in 50 ml ethanol, 5 ml of water and 5 ml of acetic acid, containing 0.5 g of 10% palladium on charcoal, are mixed, simultaneously iiponycxioioT through a solution of hydrogen through a feed pipe. The reaction is continued for 3 hours, after which the solution is filtered and concentrated. The residue is stirred with water and the residue is concentrated with a concentrated solution of ammonium hydroxide, resulting in the formation of a gummy material. It is extracted with ethyl acetate:, dried over sodium sulfate, and the solution is concentrated. The residue is stirred with diethyl ether and filtered. Obtain 1.4 g of the product with so pl. 82-92 ° C. The latter is recrystallized from 10 ml of ethyl acetate, adding to it a few drops of triethytamine, and 0.84 g of product is obtained with a volume of 105-107 ° C. .55 Using 1-2-chloro-H- 3- 4- (methyl c, ulfonyl) phenyl -2-oxooxazolidin-5-ylmethyl1-acetamide, as in Example 96 part A, the proposed compound with m.p. 188.8-189.8 С Example 98. N- - (4-acetylphenyl) -2-oxooxazolidin-5-ylmethyl - acetaminoxime (1; A, In NHCOCH). 3.16 g of (4-acetylphenyl) -2-oxoxazolidin-5-ylmethyl-acetamide is dissolved in a mixture of 20 ml of pyridine with 20 ml of ethanol, and 5 g of hydroxylamine hydrochloride is added to the solution. The mixture is kept at reflux temperature for 2 hours. After spontaneously cooling to room temperature, the solvents are added and the residue is triturated in a dilute aqueous solution of hydrochloric acid. The solids are separated and washed with water. By recrystallization from aqueous ethanol, 1.6 g of pure (D-acetylphenyl) -2-oxooxazolidin-5-ylmethyl-acetamidoxime with mp. 213-215 ° C. Example 99 (4-acetylphyl) -2-oxooxazolidin-5-ylmethyl-acetamidoxime, methyl ester (I; A CHjC; In NHCOCH,). MOSNg Using methoxylamine hydrochloride instead of hydroxylamine hydrochloride and working as in Example 98, 1.8 g of N-L3- (4-acetylphenyl) -2-oxooxazolidin-5-ylmethyl-acetamidoxime methyl ester are obtained, m.p. 208-211 ° C. Dosage forms The antibacterial suggested compounds of the formula I can be introduced into the body by any means that ensure that the active substance is brought into contact with the place of action of the substance in the body of a mammal. They can be administered in combination with pharmaceuticals, either as individual therapeutic agents, or in combination with therapeutic agents. They can be administered individually, but are usually administered into the body in combination with a pharmaceutical carrier, selected on the basis of the chosen route of administration and the established pharmaceutical practice. Dosages administered will vary with these factors. 0 five five n c tori, as the pharmacodynamic characteristics of the agent specifically used, the method and route of administration in the body; age, health, and weight of the patient; the nature and extent of the symptoms of the disease, the type of concurrent treatment, the frequency of treatment and the target effect. Typically, the daily dosage of active ingredient of the substance is about 5-20 mg / kg of live weight. Usually, when a more potent proposed compound is used, the desired effect is achieved with the administration of 5-15, preferably 5-7.5 mg / kg of live weight per day, and these doses are divided into fractional dosages for daily administration from 2 to 4 times or used in a form that provides a constant release of the active substance. Such drugs can also be entered into the body parenterally. Dosage forms suitable for oral administration contain about 1.0-500 mg of active ingredient per unit (dosage). In these pharmaceutical compositions, the active component is typically present in an amount of about 0.5-95% by weight, based on the total weight of the composition. Useful pharmaceutical dosage forms for administering the compounds of the invention to the body can be illustrated by the following examples. Capsules A number of individual capsules are prepared by filling standard two-component hard gelatin capsules, each of which is filled with 75 ml of powdered active ingredient, 150 mg of lactose, 24 mg of talc and 6 mg of magnesium stearate. Soft gelatin capsules. Prepare a mixture of the active ingredient with soybean oil, after which the mixture is injected into a gelatin container with the help of an injection piston pump to form soft gelatin capsules containing 75 mg of the active ingredient. Further, such capsules are washed and dried. 0 five 0 Pills. A number of tablets are prepared in such a way that the dosage unit includes the substance 1315 75 mg of active anti-0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate 250 mg of microcrystalline cellulose, 11 mg of corn starch and 98.8 mg of lactose. Appropriate coatings can be applied to increase the palatability or delay the absorption. Injections. A parenteral composition suitable for administration by injection is prepared by mixing 1.5 mas. active ingredient c 10 ob.7, propylene glycol and water. By adding sodium chloride, the solution is made isotonic and sterilized. Suspension. Bodno suspension is prepared for oral administration in such a way that each 5 ml of it contains 75 mg of a finely dispersed active substance, 200 mg of sodium carboxymethylcellulose, 5 mg of sodium benzoate, 1.0 g of aorbitol solution and 0.025 ml of vanillin. Test The test results show that the proposed compounds of the formula I are biologically active against gram-positive and gram-negative bacteria, including cultures of Staphylococcus aureus, producing δ-lactamase. These agents are potentially useful in treating contagious diseases in both humans and animals, including respiratory tract diseases, gastrointestinal diseases, urogenital diseases, and diseases of the central nervous system. we, blood, interstitial fluids, soft tissues and bones. The compounds of formula I exhibit an antibacterial effect in vitro. To determine 24-hour minimum inhibitory concentrations (MIC) 14 0 five 0 in relation to experimental strains of Staphylococcus epidermidis and Escherichia coli microorganisms, Müller-Hinton liquid is used in accordance with the standard micro-dilution method. The results are shown in Table. four. Determination of the effectiveness of the innocence of the wire 1 by intraperitoneally injecting into the body of young cultures of infecting microorganisms diluted with regard to the attainment of 90-100% mortality in control animals during Ce MJi days. Trypticase soybean liquid medium for E coli microorganisms and 5% aqueous solution of mucin of the stomach of the pig for Staphylococcus aureus microorganisms are used as diluents. The test compounds are dissolved or suspended in a 0.25% aqueous solution of the product Metosel R (Metosel Cgloxypropylmethylcellulose E15, 5 manufactured by Dow Chemical Company) for administration through the mouth or in sterile distilled water containing 5% dimethyl sulfoxide (Fisher Shertifik company, Fairlone, NJ) for subcutaneous administration. These compounds in certain dosages are administered during infection and again after 4 hours of infection. Mortality was recorded daily until completion of the tests, and the 50% effective dosage, ED, is calculated according to the Reed-Münk method The proposed therapeutic levels for humans should be achieved with the introduction through the mouth in the amount of 5-20 mg / kg of live weight in the form of fractional dosages taken daily from 2 to 4 times. For serious or life-threatening infections, the indicated dosages may be increased. The results are presented in table.5 and 6. 0 five 0 five 15 Structure and characteristics of compounds of the formula Table Structure and characteristics of compounds of the formula Table 3 Structure and characteristics of compounds of the formula 1505442 Table sixteen one L ABOUT L-k NHi tatna salt Continued table. 3 nineteen Table 4 Minimum inhibitory concentration, dilution of the liquid medium during in vitro tests 6.3 200.0 200.0 100.0 50.0 100.0 200.0 200.0 6.3 2.4 3.2 100.0 6.3 6.3 12.5 12.5 200.0 150544220 Continuation of table 3 100.0 200.0 200.0 .200.0 100.0 100.0 200.0 , 0 100.0 9.4 25.0 100.0 100.0 50.0 5070 100.0 200.0 150544224 Table 5 The effectiveness of the compounds in vivo when they are introduced through the mouth into the body of mice infected with intraperitoneal injection 25 E0 „ Bacterial microorganisms Staphylococcus aureus 64.0 47.9 2.7 9.6 11.0 11.3 50.7 31.0 120.0 30.2 10.9 7.9 0.70 3.0 4.4 N.T. 58-, 9 11.4 6.5 5.1 Note. NT - not tested. Table The efficacy of compounds in vivo when they are subcutaneously injected into organics with mice infected with intraperitoneal injection 1505442 Continuation of the table. 26 Eachjerichia coli N.T. 120.0 65.9 120.0 138.0 98.4 N.T. N.T. N.T. 76.8 120.0 83.2 13.6 17.9 46.9 100.0 N.T. 56.5 71.5 105.3 27 G emechen. NT is not tested. Compiled by 3. Latypova Editor N. Kishtulinets Tehred M. Morgental Corrector O. Kravtsova Order 5272/58 Circulation 352 VNIIPI State Committee for Inventions and Discoveries at the State Committee on Science and Technology of the USSR 113035, Moscow, Zh-35, Raushsk nab., D / 5 Production and publishing plant Patent, Uzhgorod, st. G lgarina, 101 I505AA228 Continued table. 6 Subscription
权利要求:
Claims (2) [1] The method of obtaining oxazolidinone derivatives of the formula '-at in the form of 1-isomers or a mixture of 8- and 1-isomers, where Υ is hydrogen; A - is in position 3 of the benzene ring and means C 4 -C 4 -acyl, C, - C 2 -alkyl, methoxy, methylthio, trifluoromethyl or nitro group, or A is in position 4 of the benzene ring and means C, -C ^ -alkyl, optionally substituted with 1-3 halogen atoms, -alkenyl, cyano-, C, -C ^ -alkoxy-, C, -C 4 ~ alkylthio, C, -c + alkylsulfinyl, C, -C4-alkyl ~ [2] 2 sulfonyl, a group of the formula -SODgde K, is hydrogen, C 4 -C ^ -alkyl or cyclohexyl, or a group of the formula νκ 2 -C- CH 3 where K ( is hydroxy or methoxy, or Υ and A together form 3,4-methylenedioxyg.p; B - azido-, amino-C, -C + -alkanesulfonamido- or a group of the formula about -KNSK 3 where is hydrogen, C 1 -C 4 -alkenyl, C, -C ^ -alkyl, substituted with 1-3 halogen atoms, C 2 -alkenyl, acetyl, cyclopropyl, phenyl, C 4 -C 4 -alkoxy, C, -C ^ alkoxymethyl, di ^ (C (-C 2 -alkoxy) methyl, amino, methylamino, pyruvoylamino group, ib-aminobenzyl, aminomethyl or aidomethyl; with the proviso that when A is a cyano group, B cannot designate an aero group, or when A is isopropyl, B cannot designate a chloroacetylamino group, or if there is a free amino group in substituent B of their acid addition salts with. · I’m liking the fact that 15 1505442 AZ h 1505442 four in the form of a 1-isomer or a mixture of 6- and 1-isomers, where Υ and A have the indicated meanings; B - iodine or hydroxy group in the form salts with p-toluenesulfonic acid are reacted with an alkali metal azide when heated in an inert organic solvent and the target product, where B is, the azido group is isolated or, if necessary, transferred to the target product, where B is an amino group, by reduction and the target product, where B is an amino group, if necessary, 1 is reacted with C ^ -C ^ alkanesulfonyl chloride or with anhydride, carboxylic ester or carboxylic ester acid formula 2 c's „I G. where K has the values indicated for k, in addition to aminomethyl or azidomethyl, 1 and the target product, where K 3 is chloromethyl, if necessary, is reacted with an alkali metal azide when heated in an inert organic solvent and the desired product, - azidomethyl, if necessary, is transferred to the target product, where K, is aminomethyl, by reduction and, if necessary, in the presence of a free amino group, the target product is isolated as an additive salt with an acid. Priority featured: 06.06.83 with Υ - hydrogen; A is in position 4 of the benzene ring and means C, -C 4 -alkylthio, C <-C 4 -alkylsulfinyl or C, -C 4 ~ alkylsulfonyl; B has the indicated meanings. 14.02.84 with Υ - hydrogen; A is in position 3 of the benzene ring and means C ^ -C 4 ~ acyl, C, -C 2 alkyl, methoxy, methylthio, trifluoromethyl or nitro, or A is in position 4 of the benzene ring and means C, -C 4 -alkyl optionally substituted with 1 to 3 halogen atoms, C 1 -C 4 alkenyl, cyano, C, -C 4 alkoxy, a group of the formula SOK, in which K <is hydrogen, C, -C4-alkyl or cyclohexyl or group of formula T 2 - cn 3 where K 2 is a hydroxy or methoxy group, or Υ and A vseta form 3,4 methylenedioxy group, B has the indicated values.
类似技术:
公开号 | 公开日 | 专利标题 SU1505442A3|1989-08-30|Method of producing derivatives of oxazolidinon as l-isomers or mixture of d- and l-isomers, or their acid-additive salts EP0184170B1|1991-10-16|Aminomethyl oxooxazolidinyl benzene derivatives useful as antibacterial agents US4461773A|1984-07-24|P-Oxooxazolidinylbenzene compounds as antibacterial agents EP0316594B1|1993-09-29|Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents DE60221684T2|2008-04-30|ANTIBIOTICS WITH DOUBLE EFFECT EP0311090A1|1989-04-12|Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents EP0312000A1|1989-04-19|Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents HU229577B1|2014-02-28|9-substituted minocycline derivatives US20060211603A1|2006-09-21|Ramoplanin derivatives possessing antibacterial activity EP1650186B1|2008-06-04|Novel dicarboxylic acid derivatives HU230061B1|2015-06-29|Cycloalkene derivatives, process for producing the same, and use JP2004502755A|2004-01-29|Pleuromutilin derivatives with antibacterial activity US9765105B2|2017-09-19|Macrolide compound MXPA02011160A|2003-03-10|Phosphate transport inhibitors. EP3464236A1|2019-04-10|Compounds and methods for hematopoietic regeneration EA019579B1|2014-04-30|Mutilin derivatives and their use as pharmaceuticals JP2009520813A|2009-05-28|Carbamate antibiotics US4914202A|1990-04-03|Morpholine compounds CS227012B2|1984-04-16|Method of preparing 2-amino-3-benzoyl-phenylacetamide JP6890865B1|2021-06-18|Cyclic amide compounds for the treatment of rabies and methods thereof SU1711673A3|1992-02-07|Method for the synthesis of ethanolamine or theirs physiologically acceptable salts or solvates JP2009519269A|2009-05-14|Diphenylurea derivative EP0081200A1|1983-06-15|p-Oxooxazolidinylbenzene sulfonamides as antibacterial agents HU186856B|1985-10-28|Process for preparing 3-/p-alkyl-sulphonyl-phenyl/-oxazolidinone derivatives and pharmaceutical compositions containing such compounds
同族专利:
公开号 | 公开日 MX169619B|1993-07-15| ES8506659A1|1985-08-01| DK279584A|1984-12-08| EP0127902A3|1987-09-02| NO163451B|1990-02-19| FI83216B|1991-02-28| NO163451C|1990-05-30| HU194194B|1988-01-28| DK279584D0|1984-06-06| ES8802037A1|1988-03-16| HUT34462A|1985-03-28| FI842273A0|1984-06-06| AU2909984A|1984-12-13| IL72028A|1988-05-31| ES533097A0|1985-08-01| DE3485162D1|1991-11-21| CA1254213A|1989-05-16| IE57619B1|1993-02-10| CA1275652C|1990-10-30| NO842273L|1984-12-10| IL72028D0|1984-10-31| SU1426451A3|1988-09-23| PT78703A|1984-07-01| FI842273A|1984-12-08| ES540812A0|1988-03-16| EP0127902A2|1984-12-12| GR82361B|1984-12-13| FI83216C|1991-06-10| AU583250B2|1989-04-27| EP0127902B1|1991-10-16| NZ208395A|1987-07-31| IE841407L|1984-12-07|
引用文献:
公开号 | 申请日 | 公开日 | 申请人 | 专利标题 GB1222708A|1968-10-22|1971-02-17|Delalande Sa|Novel 5--2-oxazolidinones and their process of preparation| US4348393A|1978-06-09|1982-09-07|Delalande S.A.|N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones| US4340606A|1980-10-23|1982-07-20|E. I. Du Pont De Nemours And Company|3-oxazolidinone derivatives as antibacterial agents| FR2500450B1|1981-02-25|1983-12-02|Delalande Sa| ES8401951A1|1981-12-04|1984-01-16|Du Pont|p-Oxooxazolidinylbenzene sulfonamides as antibacterial agents.| CA1260948A|1984-12-05|1989-09-26|E. I. Du Pont De Nemours And Company|Aminomethyl oxooxazolidinyl benzene derivativesuseful as antibacterial agents|US4705799A|1983-06-07|1987-11-10|E. I. Du Pont De Nemours And Company|Aminomethyl oxooxazolidinyl benzenes useful as antibacterial agents| CA1260948A|1984-12-05|1989-09-26|E. I. Du Pont De Nemours And Company|Aminomethyl oxooxazolidinyl benzene derivativesuseful as antibacterial agents| US5099026A|1986-09-12|1992-03-24|Crater Davis H|Fluorochemical oxazolidinones| CA1323370C|1986-09-12|1993-10-19|Davis H. Crater|Fluorochemical oxazolidinones| US4921869A|1987-10-09|1990-05-01|E. I. Du Pont De Nemours And Company|Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents| US4801600A|1987-10-09|1989-01-31|E. I. Du Pont De Nemours And Company|Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents| US5036092A|1987-10-09|1991-07-30|Du Pont Merck Pharmaceutical|Aminomethyl oxooxazolidinyl azacycloalkylbenzene derivatives useful as antibacterial agents| US4985429A|1987-10-09|1991-01-15|E. I. Du Pont De Nemours And Company|Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents| US4965268A|1987-10-09|1990-10-23|E. I. Du Pont De Nemours And Company|Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents| US5032605A|1987-10-09|1991-07-16|Du Pont Merck Pharmaceutical Company|Aminomethyl oxooxazolidinyl oxa or thia cycloalkylbenzene derivatives useful as antibacterial agents| US5036093A|1987-10-09|1991-07-30|Du Pont Merck Pharmaceutical|Aminomethyl oxooxazolidinyl azacycloalkylbenzene derivatives useful as antibacterial agents| US5039690A|1987-10-09|1991-08-13|Du Pont Merck Pharmaceutical Company|Aminomethyl oxooxazolidinyl oxa or thia cycloalkylbenzene derivatives useful as antibacterial agents| US4942183A|1987-10-16|1990-07-17|E. I. Du Pont De Nemours And Company|Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents| CA1320730C|1987-10-16|1993-07-27|The Du Pont Merck Pharmaceutical Company|Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents| US4977173A|1987-10-21|1990-12-11|E. I. Du Pont De Nemours And Company|Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents| DE3884563T2|1987-10-21|1994-02-17|Du Pont Merck Pharma|Aminomethyl oxo oxazolidinyl ethenyl benzene derivatives useful as an antibacterial agent.| US4948801A|1988-07-29|1990-08-14|E. I. Du Pont De Nemours And Company|Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents| US5182403A|1988-09-15|1993-01-26|The Upjohn Company|Substituted 3 oxazolidin-2-ones| EP0359418B1|1988-09-15|1994-10-12|The Upjohn Company|5'-Indolinyl-5beta-amidomethyloxazolidin-2-ones, 3-phenyl-5beta-amidomethyloxazolidin-2-ones and 3-phenyl-5beta-amidomethyloxazolidin-2-ones| US5225565A|1988-09-15|1993-07-06|The Upjohn Company|Antibacterial 3-phenyl-5β-amidomethyloxazolidin-2-ones| US5231188A|1989-11-17|1993-07-27|The Upjohn Company|Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents| DE69216251T2|1991-11-01|1997-05-15|Upjohn Co|SUBSTITUTED ARYL AND HETEROARYL PHENYLOXAZOLIDINONE| DK0673370T3|1992-12-08|1998-09-07|Upjohn Co|Tropon-substituted phenyloxazolidinones as antibacterial agents| TW299332B|1992-12-08|1997-03-01|Upjohn Co| US5688792A|1994-08-16|1997-11-18|Pharmacia & Upjohn Company|Substituted oxazine and thiazine oxazolidinone antimicrobials| MY115155A|1993-09-09|2003-04-30|Upjohn Co|Substituted oxazine and thiazine oxazolidinone antimicrobials.| US5883093A|1995-09-12|1999-03-16|Pharmacia & Upjohn Company|Phenyloxazolidinone antimicrobials| EP0788498B1|1994-10-26|2001-08-16|PHARMACIA & UPJOHN COMPANY|Phenyloxazolidinone antimicrobials| GB9601666D0|1996-01-27|1996-03-27|Zeneca Ltd|Chemical compounds| GB9702213D0|1996-02-24|1997-03-26|Zeneca Ltd|Chemical compounds| GB9609919D0|1996-05-11|1996-07-17|Zeneca Ltd|Chemical compounds| US6255304B1|1997-05-30|2001-07-03|Pharmacia & Upjohn Company|Oxazolidinone antibacterial agents having a thiocarbonyl functionality| CA2288750A1|1997-05-30|1998-12-03|Pharmacia & Upjohn Company|Oxazolidinone antibacterial agents having a thiocarbonyl functionality| GB9717807D0|1997-08-22|1997-10-29|Zeneca Ltd|Chemical compounds| GB9717804D0|1997-08-22|1997-10-29|Zeneca Ltd|Chemical compounds| AU9001598A|1997-09-11|1999-03-29|Hokuriku Seiyaku Co. Ltd|Thiourea derivatives| GB9725244D0|1997-11-29|1998-01-28|Zeneca Ltd|Chemical compounds| US6239152B1|1998-01-23|2001-05-29|Pharmacia & Upjohn Company|Oxazolidinone combinatorial libraries, compositions and methods of preparation| GB9821938D0|1998-10-09|1998-12-02|Zeneca Ltd|Chemical compounds| CA2372233A1|1999-05-27|2000-12-07|Pharmacia & Upjohn Company|Bicyclic oxazolidinones as antibacterial agent| US6297242B1|1999-08-12|2001-10-02|Ortho-Mcneil Pharmaceutical, Inc.|N-substituted amidine and guanidine oxazolidinone antibacterials and methods of use thereof| GB9928568D0|1999-12-03|2000-02-02|Zeneca Ltd|Chemical compounds| US6518285B2|1999-12-21|2003-02-11|Ortho Mcneil Pharmaceutical, Inc.|Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials| DE19962924A1|1999-12-24|2001-07-05|Bayer Ag|Substituted oxazolidinones and their use| GB0009803D0|2000-04-25|2000-06-07|Astrazeneca Ab|Chemical compounds| EP1328509B1|2000-10-17|2006-03-22|Pharmacia & Upjohn Company LLC|Methods of producing oxazolidinone compounds| DE10129725A1|2001-06-20|2003-01-02|Bayer Ag|Combination therapy of substituted oxazolidinones| DE10300111A1|2003-01-07|2004-07-15|Bayer Healthcare Ag|Process for the preparation of 5-chloro-N --2-oxo-3- [4-phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide| DE10355461A1|2003-11-27|2005-06-23|Bayer Healthcare Ag|Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases| EP1685841A1|2005-01-31|2006-08-02|Bayer Health Care Aktiengesellschaft|Prevention and treatment of thromboembolic disorders| DE102005045518A1|2005-09-23|2007-03-29|Bayer Healthcare Ag|New 5-thienylaminocarbonylmethyl-oxazolidin-2-one derivatives, useful for treating and preventing thromboembolic disease, are selective inhibitors of coagulation factor Xa| DE102005047561A1|2005-10-04|2007-04-05|Bayer Healthcare Ag|Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N--2-oxo-3--phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance| US8188270B2|2005-10-04|2012-05-29|Bayer Schering Pharma Aktiengesellschaft|Polymorphous form of 5-chloro-N--2-oxo-3[4--phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide| KR101653570B1|2011-03-30|2016-09-02|주식회사 레고켐 바이오사이언스|Novel Oxazolidinone derivatives and Pharmaceutical Compositions Comprising the Same|
法律状态:
优先权:
[返回顶部]
申请号 | 申请日 | 专利标题 US50189783A| true| 1983-06-07|1983-06-07| US57833284A| true| 1984-02-14|1984-02-14| 相关专利
Sulfonates, polymers, resist compositions and patterning process
Washing machine
Washing machine
Device for fixture finishing and tension adjusting of membrane
Structure for Equipping Band in a Plane Cathode Ray Tube
Process for preparation of 7 alpha-carboxyl 9, 11-epoxy steroids and intermediates useful therein an
国家/地区
|